This is consistent with previous studies using non-selective HDAC inhibitors [38, 39], but in contrast to our previous studies using an HDAC1/3-targeting compound, HDACi 4b, where fewer EM48-(+) aggregates were detected in the cortex of HD mice treated with this drug [16]. This evidence concerns the gene HDAC9 and Huntington disease.